# OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery.

*genai · news · 2026-04-17 · Los Angeles Times*

## Key points

- OpenAI launched GPT-Rosalind, an AI model specifically built for life sciences research applications.
- GPT-Rosalind will first be available to select business customers, including Amgen, Moderna, and the Allen Institute.
- Shares of several drug discovery companies dropped sharply after OpenAI announced its new AI model.
- OpenAI has implemented high-precision flags in GPT-Rosalind to detect potential bioweapons-related activity.

**Companies:** OpenAI, Alphabet Inc., Amgen Inc., Moderna Inc., IQVIA Holdings Inc., Charles River Laboratories International Inc., Recursion Pharmaceuticals Inc., Schrodinger Inc.
**Countries:** United States

[Read the full story on Los Angeles Times](https://www.latimes.com/business/story/2026-04-17/openai-takes-on-google-with-new-ai-designed-to-speed-drug-discovery)

---

Canonical: https://newsio.io/n/e1c44924-218e-4aeb-ada9-fc0c9e9d96f0/openai-is-rolling-out-an-early-version-of-an-artificial-intelligence-model-desig
Summarized by Newsio from Los Angeles Times. https://newsio.io/how-it-works